91. Fugh-Berman A., McDonald C.P., Bell A.M., et al. Promotional tone in reviews of menopausal hormone therapy after the women’s health initiative: an analysis of published articles. PLoS Med. 2011; 8: e1000425.
92. Singer N. Medical papers by ghostwriters pushed therapy. New York Times. 2009 Aug 4.
93. Rosenberg M. Pfizer’s ghostwritten journal articles are still standing, still bogus. Online Journal. 2010 Feb 23.
94. Gøtzsche P.C. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.
195. Conflicts of interest in biomedical research. Canada’s Voice for Academics. 2003; 50: Feb.
196. Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Cent Rep. 2004; 34: 18–23.
197. Willman D. How a new policy led to seven deadly drugs. Los Angeles Times. 2000 Dec 20.
198. Bindslev J.B., Schroll J., Gøtzsche P.C., et al. Underreporting of confl icts of interest in clinical practice guidelines: cross-sectional study. BMC Med Ethics. 2013; 14: 19.
199. Steinbrook R. Controlling confl ict of interest – proposals from the Institute of Medicine. N Engl J Med. 2009; 360: 2160–3.
100. Zinner D.E., Bolcic-Jankovic D., Clarridge B., et al. Participation of academic scientists in relationships with industry. Health Aff. 2009; 28: 1814–25.
101. Lenzer J. French guidelines are pulled over potential bias among authors. BMJ. 2011; 342: d4007.
102. Clinard M.B., Yeager P.C. Corporate Crime. New Brunswick: Transaction Publishers; 2006.
103. Reuters. Factbox – The 20 largest pharmaceutical companies. 2010 Mar 26. Available online at: www.reuters.com/article/2010/03/26/pharmaceutical-mergers-idUSN2612865020100326 (accessed 17 June 2012).
104. Wikipedia. List of countries by GDP (nominal). Available online at: http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal) (accessed 30 June 2012).
105. Annas G.J. Corporations, profi ts, and public health. Lancet. 2010; 376: 583–4.
106. Thomas K., Schmidt M.S. Glaxo agrees to pay $3 billion in fraud settlement. New York Times. 2012 July 2.
107. Khan H., Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case. ABC News. 2010 April 27.
108. Brynner R., Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.
109. House of Commons Health Committee. The Infl uence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).
110. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283: 373–80.
111. Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
112. Ziegler M.G., Lew P., Singer B.C. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 1296–8.
113. Dana J., Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003; 290: 252–5.
114. Moynihan R., Heath I., Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002; 324: 886–91.
115. Campbell E.G. Doctors and drug companies: scrutinizing infl uential relationships. N Engl J Med. 2007; 357: 1796–7.
116. Steinman M.A., Shlipak M.G., McPhee S.J. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001; 110: 551–7.
117. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.
118. Campbell E.G., Gruen R.L., Mountford J., et al. A national survey of physician-industry relationships. N Engl J Med. 2007; 356: 1742–50.
119. Lenzer J. Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers. BMJ. 2011; 342: d2929.
120. Campbell E.G., Weissman J.S., Ehringhaus S., et al. Institutional academic industry relationships. JAMA. 2007; 298: 1779–86.
121. Revill J. Doctor accuses drug giant of ‘unethical’ secrecy. Observer. 2005 Dec 4.
122. Steinbrook R. Physician-industry relations – will fewer gifts make a difference? N Engl J Med. 2009; 360: 557–9.
123. Roehr B. US Institute of Medicine report calls for an end to fi rms’ drug and device promotion to doctors. BMJ. 2009; 338: 1100.
124. Steinman M.A., Landefeld C.S., Baron R.B. Industry support of CME – are we at the tipping point? N Engl J Med. 2012; 366: 1069–71.
125. Norris S.L., Holmer H.K., Ogden L.A., et al. Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study. BMC Medical Ethics. 2012; 13: 24.
126. Arnfred C.E., Pedersen L.N., Agger C. [Politicians feel cheated by lobby-doctors]. Jyllandsposten. 2011 Aug 29.
127. Thirstrup S. [Can you sell diseases]? Rationel Farmakoterapi. 2010 Dec.
128. Borg O. [Pill ads are distributed in school yards]. Jyllands-Posten. 2011 Nov 1.
129. Herxheimer A. Relationships between the pharmaceutical industry and patients’ organisations. BMJ. 2003; 326: 1208–10.
130. Rathje M. [Heart Association scares the Danes]. TV2 News. 2012 April 20.
131. Cassidy J. The International Alliance of Patients’ Organizations. BMJ. 2011; 342: d3485.
132. [Danish Association of the Pharmaceutical Industry’s collaboration with patient associations and others in 2010]. 2010. Available online at: www.lifdk.dk/graphics/Lif/Inside%20Lif/2011/09/Medlemmers%20samarbejde%20med%20patientforeninger%20m.v.%202010.pdf (accessed 28 June 2011).
133. Wolfe S. The seven-year rule for safer prescribing. Aust Prescr. 2012; 35: 138–9.
134. Jelinek G.A., Brown A.F. A stand against drug company advertising. Emergency Medicine Australasia. 2011; 23: 4–6.
135. Altman D.G. The scandal of poor medical research: we need less research, better research, and research done for the right reasons. BMJ. 1994; 308: 283–4.
136. Lexchin J., Light D.W. Commercial infl uence and the content of medical journals. BMJ. 2006; 332: 1444–7.
